
Shares of cancer therapy developer Arcellx ACLX.O rise 77.5% to $113.78 premarket
Gilead Sciences GILD.O says it will buy ACLX for an implied equity value of $7.8 billion
The implied equity value includes $115 per share in cash at closing and one contingent value right of $5 per share
Up to last close, ACLX stock had fallen 1.7% YTD